3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
2
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Breast Neoplasms
8
Lung Neoplasms
5
Colorectal Neoplasms
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Hot Flashes
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
COVID-19
2
Brain Neoplasms
2
Water-Electrolyte Imbalance
1
Ventilator-Induced Lung Injury
1
Surgical Wound
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Severe Acute Respiratory Syndrome
1
Rectal Neoplasms
1
Postoperative Complications
1
Pathologic Complete Response
1
Neoplasm, Residual
1
Mastocytosis
1
Lymphopenia
1
Lymphoma, Non-Hodgkin
1
Lymphedema
1
Lower Urinary Tract Symptoms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Hairy Cell
1
Hypersensitivity
1
Interventions
Temozolomide
154
Bevacizumab
88
Radiotherapy
75
Radiation
23
Magnetic Resonance Spectroscopy
23
Lomustine
18
Irinotecan
18
pembrolizumab
17
Surgical Procedures, Operative
16
Carmustine
16
Erlotinib Hydrochloride
12
Nivolumab
11
Specimen Handling
10
Aminolevulinic Acid
10
sargramostim
9
Thalidomide
9
Chemotherapy, Adjuvant
9
Carboplatin
9
Drug Therapy
8
Immunoglobulin G
7
Filgrastim
7
Etoposide
7
Disulfides
7
Cilengitide
7
Sunitinib
6
Sorafenib
6
O(6)-benzylguanine
6
Cyclophosphamide
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Glioblastoma
×
Sodium Chloride
×
Clear all
NCT02465268
2025-01-14
ATTAC-II
University of Florida
Phase 2
Completed
175 enrolled
18 charts
NCT02366728
2023-06-08
ELEVATE
Duke University
Phase 2
Completed
64 enrolled
17 charts